Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies

BACKGROUND: Long-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug–device combination of the LAMA glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebulizer. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Donohue, James F., Goodin, Thomas, Tosiello, Robert, Wheeler, Alistair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715551/
https://www.ncbi.nlm.nih.gov/pubmed/29202767
http://dx.doi.org/10.1186/s12931-017-0681-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715551/
https://www.ncbi.nlm.nih.gov/pubmed/29202767
http://dx.doi.org/10.1186/s12931-017-0681-z

Ejemplares similares